WO1998016202B1 - Fusogenic liposome composition and method - Google Patents
Fusogenic liposome composition and methodInfo
- Publication number
- WO1998016202B1 WO1998016202B1 PCT/US1997/018838 US9718838W WO9816202B1 WO 1998016202 B1 WO1998016202 B1 WO 1998016202B1 US 9718838 W US9718838 W US 9718838W WO 9816202 B1 WO9816202 B1 WO 9816202B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- hydrophilic polymer
- liposomes
- chains
- liposome
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title claims abstract 33
- 239000000203 mixture Substances 0.000 title claims abstract 24
- 230000000799 fusogenic Effects 0.000 title claims abstract 3
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract 27
- 210000004027 cells Anatomy 0.000 claims abstract 22
- 229920001600 hydrophobic polymer Polymers 0.000 claims abstract 17
- 239000011248 coating agent Substances 0.000 claims abstract 8
- 238000000576 coating method Methods 0.000 claims abstract 8
- 150000001875 compounds Chemical class 0.000 claims abstract 4
- 230000004927 fusion Effects 0.000 claims abstract 4
- 210000000170 Cell Membrane Anatomy 0.000 claims abstract 2
- 230000003993 interaction Effects 0.000 claims abstract 2
- 230000027455 binding Effects 0.000 claims 17
- 239000003446 ligand Substances 0.000 claims 12
- 239000000126 substance Substances 0.000 claims 11
- -1 polymethyloxazoline Polymers 0.000 claims 9
- 150000002632 lipids Chemical class 0.000 claims 8
- 239000000725 suspension Substances 0.000 claims 6
- 239000012528 membrane Substances 0.000 claims 4
- 239000003638 reducing agent Substances 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2S,4S,5R,6R)-5-acetamido-2-{[(2S,3R,4S,5S,6R)-2-{[(2R,3R,4R,5R)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1R,2R)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 claims 2
- 210000003743 Erythrocytes Anatomy 0.000 claims 2
- 229940014144 Folate Drugs 0.000 claims 2
- 102000006815 Folate receptors Human genes 0.000 claims 2
- 108020005243 Folate receptors Proteins 0.000 claims 2
- 206010018910 Haemolysis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 210000004698 Lymphocytes Anatomy 0.000 claims 2
- 229920000272 Oligonucleotide Polymers 0.000 claims 2
- 229920001451 Polypropylene glycol Polymers 0.000 claims 2
- 230000009089 cytolysis Effects 0.000 claims 2
- 229920000359 diblock copolymer Polymers 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 150000002019 disulfides Chemical class 0.000 claims 2
- 230000002708 enhancing Effects 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 235000019152 folic acid Nutrition 0.000 claims 2
- 239000011724 folic acid Substances 0.000 claims 2
- 230000002949 hemolytic Effects 0.000 claims 2
- 230000002209 hydrophobic Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000002934 lysing Effects 0.000 claims 2
- 102000006240 membrane receptors Human genes 0.000 claims 2
- 108020004084 membrane receptors Proteins 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 210000004881 tumor cells Anatomy 0.000 claims 2
- 229940072107 Ascorbate Drugs 0.000 claims 1
- 229960002433 Cysteine Drugs 0.000 claims 1
- 206010015866 Extravasation Diseases 0.000 claims 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 1
- 229960003180 Glutathione Drugs 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 claims 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000004698 Polyethylene (PE) Substances 0.000 claims 1
- 239000004721 Polyphenylene oxide Substances 0.000 claims 1
- 239000004743 Polypropylene Substances 0.000 claims 1
- 239000004793 Polystyrene Substances 0.000 claims 1
- 210000003324 RBC Anatomy 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229920002083 cellular DNA Polymers 0.000 claims 1
- 229920002092 cellular RNA Polymers 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000036251 extravasation Effects 0.000 claims 1
- 235000003969 glutathione Nutrition 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims 1
- 229920000068 poly(2-ethyl-2-oxazoline) Polymers 0.000 claims 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 claims 1
- 229920000515 polycarbonate Polymers 0.000 claims 1
- 239000004417 polycarbonate Substances 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 229920000023 polynucleotide Polymers 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 229920001955 polyphenylene ether Polymers 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- 229920003288 polysulfone Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 230000001737 promoting Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229920000428 triblock copolymer Polymers 0.000 claims 1
- 210000000805 Cytoplasm Anatomy 0.000 abstract 1
Abstract
A fusogenic liposome composition for delivering a liposome-entrapped compound into the cytoplasm of a target cell is described. The liposomes have an outer surface coating of chemically releasable hydrophilic polymer chains which shield hydrophobic polymers on the liposomes outer surface. Release of the hydrophilic polymer chains exposes the hydrophobic polymers for interaction with outer cell membranes of the target cells to promote fusion of the liposome with the target cells. Also disclosed is a method for using the composition to deliver a compound to target cells, and a method for selecting suitable hydrophobic polymers for use in the composition.
Claims
1. A liposome composition for fusion with a target membrane, comprising a suspension of liposomes designed for targeting to the target membrane, where each liposome (i) contains a therapeutic agent entrapped in the liposomes, and (ii) is composed of vesicle-forming lipids, a portion of the lipids derivatized by a diblock copolymer composed of a hydrophobic polymer chain covalently bound to the lipid and a hydrophilic polymer chain, the hydrophobic and hydrophilic chains being joined by a chemically releasable bond for release of the hydrophilic polymer chains and exposure of the hydrophobic polymer chains.
2. The composition of claim 1, wherein the liposomes are further composed of vesicle-forming lipids having a hydrophilic polymer chain linked to a vesicle-forming lipid via a chemically releasable bond.
3. The composition of claim 1, wherein said releasable bond is a disulfide bond or a pH sensitive chemical linkage.
4. The composition of claim 1, wherein said hydrophilic polymer chains are composed of a hydrophilic polymer selected from the group consisting of polyvinylpyrrolidone, polyvinylmethylether, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyloxazoline, polyhydroxypropylmethacrylamide, polymethacrylamide, polydimethylacrylamide, polyhydr- oxypropylmethacrylate, polyhydroxyethylacrylate, hydroxymethylcellulose, hy- droxyethylcellulose, polyethyleneglycol, and polyaspaitamide.
5. The composition of claim 4, wherein said hydrophilic polymer chains are composed of polyethylene glycol chains having a molecular weight of between 500-10,000 daltons.
6. The composition of claim 1, wherein said hydrophobic polymer is selected from the group consisting of polypropylene oxide, polyethylene, polypropylene, polycarbonate, polystyrene, polysulfone, polyphenylene oxide and polytetramethylene ether.
7. The composition of claim 6, wherein said hydrophobic polymer is polypropylene oxide having a molecular weight of between 500-3,000 daltons. 46
8. The composition of claim 1, wherein said hydrophobic polymer is a linear polymer effective to cause hemolysis of red blood cells when a water-soluble triblock copolymer containing the hydrophobic polymer and hydrophilic polymer chains joined to opposite ends of the hydrophobic polymer chains by disulfide bonds is incubated with such cells, and the incubate is treated with a reducing agent.
9. The composition of claim 1, wherein said liposomes further contain a ligand attached to a distal end of the hydrophilic polymer chains, said ligand effective for ligand- specifϊc binding to a receptor molecule on a target cell surface prior to chemical release of the hydrophilic polymer chains.
10. The composition of claim 9, wherein said ligand is selected from the group consisting of (i) folate, where the composition is intended for treating tumor cells having cell- surface folate receptors, (ii) pyridoxyl, where the composition is intended for treating virus- infected CD4+ lymphocytes, and (iii) sialyl-Lewisx, where the composition is intended for treating a region of inflammation.
11. The composition of claim 1, wherein the liposomes further include a ligand attached to the liposome surface, said ligand being effective to bind to a target cell surface receptor molecule after, but not before, chemical release of the hydrophilic polymer chains.
12. The composition of claim 1, wherein said liposomes further contain a cationic lipid effective to impart a positive liposome-surface charge, to enhance binding of liposomes to target cells after, but not before, chemical release of the hydrophilic polymer chains.
13. The composition of claim 1, wherein the agent entrapped in the lipid vesicles is a polynucleotide capable of expressing a selected protein, when taken up by a target cell.
14. The composition of claim 1, wherein the agent entrapped in the liposomes is an oligonucleotide or oligonucleotide analog effective for sequence-specific binding to cellular
RNA or DNA.
15. A method of delivering a compound to target cells in a subject comprising parenterally administering to the subject liposomes designed for reaching the target cells via the bloodstream, each liposome containing said compound in entrapped form and having an outer surface coating of chemically releasable hydrophilic polymer chains, and 47 contacting the liposomes at the target cells with a chemical agent effective to release said chains forming said surface coating, thereby to expose hydrophobic polymers on the liposome outer surface for interaction with outer cell membranes of the target cells and promote fusion of the liposome with the target cells.
16. The method of claim 15, wherein said hydrophilic polymer chains are releasably attached to the liposome via a reducible chemical linkage, and said contacting includes administering to the subject a reducing agent effective to release said chains.
17. The method of claim 16, wherein said chemical linkage is a disulfide linkage and said reducing agent is selected from the group consisting of cysteine, glutathione and ascorbate.
18. The method of claim 15, wherein each of said hydrophilic polymer chains is releasably attached to the liposome via a pH sensitive chemical linkage, and said contacting includes targeting the liposomes to a site having a pH effective to release said chains.
19. The method of claim 18, wherein said liposomes have sizes between 0.03-0.40 m for extravasation into a solid tumor.
20. The method of claim 15, wherein said liposomes further contain a ligand attached to a distal end of the hydrophilic polymer chains, said ligand effective for ligand- specific binding to a receptor molecule on a target cell surface before chemical release of the hydrophilic polymer coating.
21. The method of claim 20, wherein said ligand is selected from the group consisting of (i) folate, where the composition is intended for treating tumor cells having cell- surface folate receptors, (ii) pyridoxyl, where the composition is intended for treating virus- infected CD4+ lymphocytes, and (iii) sialyl-Lewisx, where the composition is intended for treating a region of inflammation.
22. The method of claim 15, wherein the liposomes further include a ligand attached to the liposome surface, said ligand being effective to bind to a target cell surface receptor molecule after, but not before, chemical release of the hydrophilic polymer coating.
23. The method of claim 15, wherein said liposomes further contain a cationic lipid effective to impart a positive liposome-surface charge, to enhance binding of liposomes to target cells after, but not before, chemical release of the hydrophilic polymer coating.
24. A method for screening a hydrophobic polymer for fusogenic activity with a target membrane, comprising adding to a suspension of target cells, atriblock copolymer composed of a segment of the hydrophobic polymer to be tested, and attached to each end of the polymer segment through a chemically releasable bond, a hydrophilic polymer segment effective to solubilize the hydrophobic polymer segment in the suspension, releasing said hydrophilic polymers to expose said hydrophobic segments to said target cells; and analyzing said suspension for lysis of said target cells.
25. The method of claim 24, wherein said target cells are erythrocytes.
26. The method of claim 24, wherein said releasable linkage is a disulfide linkage, and said releasing includes adding a reducing agent to the suspension.
27. The method of claim 24, wherein said hydrophilic polymer is polyethylene glycol having a molecular weight between 1,000-5,000 daltons.
28. A polymer-lipid conjugate for use in promoting fusion between target membranes, comprising a first segment composed of a hydrophilic polymer; a second segment composed of a hydrophobic polymer, said second segment joined to said first segment by a chemically releasable bond; and attached to said second segment, a vesicle-forming lipid member. 49
STATEMENT UNDER ARTICLE 19
Claim 1 is amended to include the content of original claim 2; namely that the liposomes each contain a diblock copolymer composed of a hydrophobic polymer chain and a hydrophilic polymer chain. Support for this is inherent in original claim 2, and consistent with Fig. 1 and its description.
Claim 2 is amended to direct the claim to the embodiment where the liposomes further include hydrophilic polymer chains bound to a vesicle- forming lipid via a releasable chain. Basis for this is set forth in Fig. 1 and on page 10, lines 26-27.
Claim 3 is unchanged.
Claims 4 and 5 are amended for consistency with claim 1, by changing the word "coating" to "chains".
Claims 6-8 are unchanged.
Claim 9 is amended to remove the term "unshielded" to clarify that the ligand is attached to a distal end of the hydrophilic polymer chains, as set forth in Fig. 1 and its description.
Claim 10 is unchanged.
Claims 11-12 are amended to remove the term "shielded" to clarify that the ligand (claim 11) is attached to the liposome surface and that the cationic lipid (claim 12) imparts a liposome-surface charge. The word "coating" is replaced with "chains" for consistency with amended claim 1.
Claims 13-19 and 21 are unchanged.
Claims 20. 22. 23 are amended as set forth for claims 9, 11 and 12.
Claim 24 is amended to change "hemolysis" to "lysis", for consistency with the spirit of the claim in that the hydrophobic polymer is added to a suspension of target cells.
Claims 25-28 are unchanged.
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK97912775T DK0932391T3 (en) | 1996-10-11 | 1997-10-10 | Fusogenic liposome composition and method |
| EP97912775A EP0932391B1 (en) | 1996-10-11 | 1997-10-10 | Fusogenic liposome composition and method |
| AT97912775T ATE232086T1 (en) | 1996-10-11 | 1997-10-10 | FUSOGENIC LIPOSOME COMPOSITION AND METHODS |
| BR9712230-0A BR9712230A (en) | 1996-10-11 | 1997-10-10 | Fusogenic liposome method and composition. |
| IL12929297A IL129292A0 (en) | 1996-10-11 | 1997-10-10 | Fusogenic liposome composition and method |
| AU49878/97A AU715063B2 (en) | 1996-10-11 | 1997-10-10 | Fusogenic liposome composition and method |
| JP51862998A JP2001504093A (en) | 1996-10-11 | 1997-10-10 | Fusion liposome compositions and methods |
| CA002267904A CA2267904C (en) | 1996-10-11 | 1997-10-10 | Fusogenic liposome composition and method |
| DE69718924T DE69718924T2 (en) | 1996-10-11 | 1997-10-10 | FUSOGENIC LIPOSOME COMPOSITION AND METHOD |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2826996P | 1996-10-11 | 1996-10-11 | |
| US60/028,269 | 1996-10-11 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1998016202A2 WO1998016202A2 (en) | 1998-04-23 |
| WO1998016202A3 WO1998016202A3 (en) | 1998-07-16 |
| WO1998016202B1 true WO1998016202B1 (en) | 1998-09-03 |
Family
ID=21842486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/018838 WO1998016202A2 (en) | 1996-10-11 | 1997-10-10 | Fusogenic liposome composition and method |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5891468A (en) |
| EP (1) | EP0932391B1 (en) |
| JP (1) | JP2001504093A (en) |
| AT (1) | ATE232086T1 (en) |
| AU (1) | AU715063B2 (en) |
| BR (1) | BR9712230A (en) |
| CA (1) | CA2267904C (en) |
| DE (1) | DE69718924T2 (en) |
| DK (1) | DK0932391T3 (en) |
| ES (1) | ES2191833T3 (en) |
| HK (1) | HK1047550A1 (en) |
| IL (1) | IL129292A0 (en) |
| PT (1) | PT932391E (en) |
| TW (1) | TW520297B (en) |
| WO (1) | WO1998016202A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9439968B2 (en) | 2012-08-13 | 2016-09-13 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
| US9556110B2 (en) | 2008-11-07 | 2017-01-31 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
Families Citing this family (166)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
| US6008202A (en) * | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US20070036722A1 (en) * | 1996-10-28 | 2007-02-15 | Pal Rongved | Separation processes |
| US6331289B1 (en) | 1996-10-28 | 2001-12-18 | Nycomed Imaging As | Targeted diagnostic/therapeutic agents having more than one different vectors |
| US6210707B1 (en) * | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| AU729655B2 (en) * | 1996-11-12 | 2001-02-08 | Regents Of The University Of California, The | Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery |
| DE19745950A1 (en) * | 1997-10-17 | 1999-04-22 | Dds Drug Delivery Service Ges | Drug carrier particle for site specific drug delivery, especially to CNS |
| US6426086B1 (en) * | 1998-02-03 | 2002-07-30 | The Regents Of The University Of California | pH-sensitive, serum-stable liposomes |
| US6372720B1 (en) | 1998-02-05 | 2002-04-16 | Kenneth J. Longmuir | Liposome fusion and delivery vehicle |
| US6936729B2 (en) * | 1998-05-16 | 2005-08-30 | Mirus Bio Corporation | Compound containing a labile disulfide bond |
| US7087770B2 (en) | 1998-05-16 | 2006-08-08 | Mirus Bio Corporation | Compound containing a labile disulfide bond |
| EP1121102B1 (en) * | 1998-09-16 | 2003-04-23 | Alza Corporation | Liposome-entrapped topoisomerase inhibitors |
| CA2353593A1 (en) * | 1998-12-18 | 2000-06-22 | Hadasit Medical Research Services & Development Ltd. | Method of administering a compound to multi-drug resistant cells |
| US6379698B1 (en) * | 1999-04-06 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Fusogenic lipids and vesicles |
| US6613352B2 (en) | 1999-04-13 | 2003-09-02 | Universite De Montreal | Low-rigidity liposomal formulation |
| US6852334B1 (en) * | 1999-04-20 | 2005-02-08 | The University Of British Columbia | Cationic peg-lipids and methods of use |
| JP5117648B2 (en) * | 1999-04-20 | 2013-01-16 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | Cationic PEG lipids and methods of use. |
| KR100642955B1 (en) * | 1999-04-23 | 2006-11-10 | 알자 코포레이션 | Releasable linkage and compositions containing same |
| US7303760B2 (en) * | 1999-04-23 | 2007-12-04 | Alza Corporation | Method for treating multi-drug resistant tumors |
| US7238368B2 (en) * | 1999-04-23 | 2007-07-03 | Alza Corporation | Releasable linkage and compositions containing same |
| IL146047A0 (en) * | 1999-04-23 | 2002-07-25 | Alza Corp | Releasable linkage and compositions containing same |
| AUPQ014699A0 (en) * | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using nanoparticles |
| AUPQ014799A0 (en) * | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
| EP1180242A1 (en) * | 1999-05-27 | 2002-02-20 | Zeptosens AG | Vesicle containing polymers and sensor detection methods based thereon |
| CZ2002140A3 (en) * | 1999-07-14 | 2002-05-15 | Alza Corporation | Neutral lipopolymer and liposome compositions containing thereof |
| AU7868400A (en) * | 1999-10-08 | 2001-04-23 | Alza Corporation | Neutral-cationic lipid for nucleic acid and drug delivery |
| US20040197390A1 (en) * | 2001-05-29 | 2004-10-07 | Shi-Kun Huang | Neutral-cationic lipid for systemic delivery of factor VIII gene |
| US7067111B1 (en) * | 1999-10-25 | 2006-06-27 | Board Of Regents, University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
| US6916488B1 (en) * | 1999-11-05 | 2005-07-12 | Biocure, Inc. | Amphiphilic polymeric vesicles |
| CA2391606A1 (en) * | 1999-11-24 | 2001-05-31 | The Liposome Company, Inc. | Modular targeted liposomal delivery system |
| US20030147944A1 (en) * | 1999-12-10 | 2003-08-07 | Mayer Lawrence D | Lipid carrier compositions with protected surface reactive functions |
| MXPA02007320A (en) * | 2000-01-28 | 2004-07-30 | Alza Corp | Liposomes containing an entrapped compound in supersaturated solution. |
| US7189705B2 (en) | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
| WO2001080900A2 (en) * | 2000-04-20 | 2001-11-01 | The University Of British Columbia | Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane |
| US10293056B1 (en) * | 2000-05-24 | 2019-05-21 | Board Of Regents, The University Of Texas System | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
| KR100784120B1 (en) | 2000-06-02 | 2007-12-12 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | EthylenedicysteineEC-drug conjugates |
| US6998115B2 (en) | 2000-10-10 | 2006-02-14 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
| USRE43612E1 (en) | 2000-10-10 | 2012-08-28 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
| EP1341497A4 (en) * | 2000-11-02 | 2005-10-19 | Smithkline Beecham Corp | Receptor antagonist-lipid conjugates and delivery vehicles containing same |
| US6613280B2 (en) | 2001-03-20 | 2003-09-02 | Therox, Inc. | Disposable cartridge for producing gas-enriched fluids |
| AU2002306821A1 (en) * | 2001-03-22 | 2002-10-08 | The Ohio State University Research Foundation | Enzyme-based anti-cancer compositions and methods |
| JP2004525138A (en) * | 2001-03-26 | 2004-08-19 | アルザ・コーポレーシヨン | Liposomal compositions for improved intracellular delivery of therapeutic agents |
| WO2002088318A2 (en) * | 2001-04-30 | 2002-11-07 | Targeted Genetics Corporation | Lipid-comprising drug delivery complexes and methods for their production |
| US20050176025A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
| US20050203040A1 (en) * | 2001-05-18 | 2005-09-15 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA) |
| US20050196765A1 (en) * | 2001-05-18 | 2005-09-08 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA) |
| US20050159382A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA) |
| US20050196767A1 (en) * | 2001-05-18 | 2005-09-08 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA) |
| US20050158735A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA) |
| US20050233997A1 (en) * | 2001-05-18 | 2005-10-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA) |
| US20050124566A1 (en) * | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA) |
| EP1572067A4 (en) * | 2001-05-18 | 2009-05-13 | Sirna Therapeutics Inc | Conjugates and compositions for cellular delivery |
| US20050288242A1 (en) * | 2001-05-18 | 2005-12-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA) |
| WO2002100317A2 (en) | 2001-05-25 | 2002-12-19 | The Trustees Of The University Of Pennsylvania | Targeted particles and methods of using the same |
| US6939564B2 (en) * | 2001-06-08 | 2005-09-06 | Labopharm, Inc. | Water-soluble stabilized self-assembled polyelectrolytes |
| AU2002368202B2 (en) | 2001-11-02 | 2008-06-05 | Insert Therapeutics, Inc | Methods and compositions for therapeutic use of RNA interference |
| GB0129121D0 (en) * | 2001-12-05 | 2002-01-23 | Ic Vec Ltd | Compound |
| US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| WO2003072091A1 (en) * | 2002-02-27 | 2003-09-04 | The Ohio State University Research Foundation | Therapeutic methods for acute myeloid leukemia |
| US7018655B2 (en) * | 2002-03-18 | 2006-03-28 | Labopharm, Inc. | Amphiphilic diblock, triblock and star-block copolymers and their pharmaceutical compositions |
| WO2003083443A2 (en) * | 2002-03-29 | 2003-10-09 | University Of Florida | Lipid mediated screening of drug candidates for identification of active compounds |
| WO2004007662A2 (en) * | 2002-04-23 | 2004-01-22 | The Research Foundation Of State University Of New York | Polymer surfactants for gene therapy applications |
| US20040022842A1 (en) * | 2002-06-03 | 2004-02-05 | Mebiopharm Co., Ltd. | Liposome preparations containing oxaliplatin |
| JP3415131B1 (en) * | 2002-06-03 | 2003-06-09 | メビオファーム株式会社 | Liposome preparation |
| US20040093198A1 (en) * | 2002-11-08 | 2004-05-13 | Carbon Design Systems | Hardware simulation with access restrictions |
| KR101177340B1 (en) † | 2003-01-06 | 2012-08-30 | 넥타르 테라퓨틱스 | Thiol-selective water-soluble polymer derivatives |
| JPWO2004063216A1 (en) * | 2003-01-10 | 2006-06-15 | アステラス製薬株式会社 | Conjugates for blood retention and cancer tissue specific drug delivery |
| WO2004078121A2 (en) * | 2003-02-28 | 2004-09-16 | Alza Coporation | Liposome composition for reduction of liposome-induced complement activation |
| CA2520864A1 (en) * | 2003-03-31 | 2004-10-21 | Alza Corporation | Lipid particles having asymmetric lipid coating and method of preparing same |
| CA2527625A1 (en) * | 2003-05-30 | 2004-12-23 | Alza Corporation | Method of pulmonary administration of an agent |
| US8846079B1 (en) * | 2004-12-01 | 2014-09-30 | Vgsk Technologies, Inc. | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal |
| US11324698B2 (en) | 2003-08-28 | 2022-05-10 | Vgsk Technologies, Inc. | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal |
| AU2004267875B2 (en) * | 2003-08-29 | 2010-09-02 | Newcastle Innovation Limited | Stimulant sensitive flocculation and consolidation |
| US7943179B2 (en) | 2003-09-23 | 2011-05-17 | Massachusetts Institute Of Technology | pH triggerable polymeric particles |
| JP2007533647A (en) * | 2003-10-24 | 2007-11-22 | アルザ・コーポレーシヨン | Preparation of lipid particles |
| US9050378B2 (en) * | 2003-12-10 | 2015-06-09 | Board Of Regents, The University Of Texas System | N2S2 chelate-targeting ligand conjugates |
| KR20060103957A (en) * | 2004-01-15 | 2006-10-04 | 알자 코포레이션 | Liposome composition for delivery of therapeutic agents |
| US8017151B2 (en) * | 2004-09-07 | 2011-09-13 | Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center | Amphiphilic polymer-protein conjugates and methods of use thereof |
| US8168222B2 (en) | 2004-09-07 | 2012-05-01 | Board Of Regents Of The University Of Nebraska | Amphiphilic polymer-protein conjugates and methods of use thereof |
| EP1809246B1 (en) * | 2004-10-08 | 2008-07-16 | Alza Corporation | Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves |
| WO2006088245A1 (en) * | 2005-02-18 | 2006-08-24 | The University Of Tokushima | Polyoxyalkylene chain-containing lipid derivative and lipid film structure containing such derivative |
| JP2006248978A (en) * | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | New liposome preparation |
| KR20080042045A (en) * | 2005-05-23 | 2008-05-14 | 에스디지,인코포레이티드 | Lipid construct for delivery of interferon to a mammal |
| WO2007008300A2 (en) | 2005-05-31 | 2007-01-18 | ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE | Triblock copolymers for cytoplasmic delivery of gene-based drugs |
| ES2594368T3 (en) | 2005-12-08 | 2016-12-19 | Insmed Incorporated | Lipid-based compositions of anti-infectives to treat lung infections |
| WO2007092944A2 (en) * | 2006-02-08 | 2007-08-16 | Introgen Therapeutics, Inc. | Compositions and methods involving gene therapy and proteasome modulation |
| US8758723B2 (en) | 2006-04-19 | 2014-06-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for cellular imaging and therapy |
| CA2654302A1 (en) | 2006-06-05 | 2007-12-13 | Massachusetts Institute Of Technology | Crosslinked, degradable polymers and uses thereof |
| US20080031883A1 (en) * | 2006-07-13 | 2008-02-07 | Torchilin Vladimir P | Condition-dependent, multiple target delivery system |
| US8343539B2 (en) * | 2006-07-14 | 2013-01-01 | Regents Of The University Of Minnesota | Compounds that bind α5β1 integrin and methods of use |
| US8071082B2 (en) | 2006-07-21 | 2011-12-06 | Massachusetts Institute Of Technology | End-modified poly(beta-amino esters) and uses thereof |
| US20080213349A1 (en) * | 2006-09-11 | 2008-09-04 | Deepak Ramesh Thakker | Liposome Complexes Containing Pharmaceutical Agents and Methods |
| MX2009003092A (en) * | 2006-09-22 | 2009-05-08 | Labopharm Inc | Compositions and methods for ph targeted drug delivery. |
| US10925977B2 (en) * | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| US20100210575A1 (en) * | 2007-06-29 | 2010-08-19 | Wisconsin Alumni Research Foundation | Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals |
| US20110105995A1 (en) * | 2008-01-16 | 2011-05-05 | Zhu Ting F | Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery |
| WO2009154688A1 (en) * | 2008-05-28 | 2009-12-23 | President And Fellows Of Harvard College | A pre-fabricated electron microscopy grid for monolayer purification and methods and kits therefor |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| CN102149749B (en) * | 2008-07-10 | 2014-06-25 | 塞瑞纳治疗公司 | Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds |
| JP5814793B2 (en) | 2008-11-25 | 2015-11-17 | エコール ポリテクニク フェデラル ド ローザンヌ（エーペーエフエル） | Block copolymer and use thereof |
| AR074977A1 (en) | 2008-12-23 | 2011-03-02 | Pharmasset Inc | SYNTHESIS OF PURINE NUCLEOSIDS |
| PT2376088T (en) | 2008-12-23 | 2017-05-02 | Gilead Pharmasset Llc | 6-o-substituted-2-amino-purine nucleoside phosphoramidates |
| CN102753563A (en) | 2008-12-23 | 2012-10-24 | 吉利德制药有限责任公司 | Nucleoside analogs |
| EP2230515B1 (en) * | 2009-03-16 | 2014-12-17 | Agilent Technologies, Inc. | Passivation of surfaces after ligand coupling |
| SG10201402054UA (en) * | 2009-05-05 | 2014-09-26 | Muthiah Manoharan | Lipid compositions |
| TWI576352B (en) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
| WO2011017297A2 (en) | 2009-08-03 | 2011-02-10 | The University Of North Carolina At Chapel Hill | Biodegradable delivery system complexes for the delivery of bioactive compounds |
| PT2474306T (en) | 2009-08-31 | 2016-12-07 | Nanocarrier Co Ltd | Particle composition and medicinal composition comprising same |
| PT2506857T (en) | 2009-12-01 | 2018-05-14 | Translate Bio Inc | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| JP4829351B2 (en) | 2010-02-05 | 2011-12-07 | ナノキャリア株式会社 | Easily disintegrating polymer micelle composition |
| CN102858790A (en) | 2010-03-31 | 2013-01-02 | 吉利德制药有限责任公司 | Nucleoside Phosphoramidates |
| US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
| WO2011123672A1 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Purine nucleoside phosphoramidate |
| WO2011140254A1 (en) | 2010-05-04 | 2011-11-10 | Adimab, Llc | Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
| WO2011160110A1 (en) | 2010-06-19 | 2011-12-22 | Western University Of Health Sciences | Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics |
| US9193827B2 (en) | 2010-08-26 | 2015-11-24 | Massachusetts Institute Of Technology | Poly(beta-amino alcohols), their preparation, and uses thereof |
| EP2632472B1 (en) | 2010-10-29 | 2017-12-13 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
| TW201242974A (en) | 2010-11-30 | 2012-11-01 | Gilead Pharmasset Llc | Compounds |
| US9238716B2 (en) | 2011-03-28 | 2016-01-19 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
| AU2012254842A1 (en) * | 2011-05-12 | 2013-05-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Liposomes comprising polymer-conjugated lipids and related uses |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| SI2717893T1 (en) | 2011-06-08 | 2019-10-30 | Translate Bio Inc | Lipid nanoparticle compositions and methods for mrna delivery |
| US8883989B2 (en) | 2011-10-18 | 2014-11-11 | Regents Of The University Of Minnesota | Fractalkine binding polynucleotides and methods of use |
| EA032088B1 (en) | 2011-10-27 | 2019-04-30 | Массачусетс Инститьют Оф Текнолоджи | Amino acid derivates functionalized on the n-terminal capable of forming drug incapsulating microspheres |
| EP3536787A1 (en) | 2012-06-08 | 2019-09-11 | Translate Bio, Inc. | Nuclease resistant polynucleotides and uses thereof |
| AU2013292636A1 (en) | 2012-07-18 | 2015-02-05 | Onyx Therapeutics, Inc. | Liposomal compositions of epoxyketone-based proteasome inhibitors |
| CN102920658B (en) * | 2012-11-02 | 2015-01-21 | 艾韦特(溧阳)医药科技有限公司 | Liposome combined with GLP-1 (Glucagon-Like Peptide-1) analogue and polyethylene glycol and preparation method of liposome |
| US10124066B2 (en) | 2012-11-29 | 2018-11-13 | Insmed Incorporated | Stabilized vancomycin formulations |
| CA2903255C (en) * | 2013-03-13 | 2018-08-28 | Mallinckrodt Llc | Modified docetaxel liposome formulations |
| AU2014236396A1 (en) | 2013-03-14 | 2015-08-13 | Shire Human Genetic Therapies, Inc. | Methods for purification of messenger RNA |
| KR102311614B1 (en) | 2013-03-14 | 2021-10-08 | 샤이어 휴먼 지네틱 테라피즈 인크. | Cftr mrna compositions and related methods and uses |
| US9315472B2 (en) | 2013-05-01 | 2016-04-19 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
| US10711106B2 (en) | 2013-07-25 | 2020-07-14 | The University Of Chicago | High aspect ratio nanofibril materials |
| CA2928078A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Lipid formulations for delivery of messenger rna |
| AU2014340092B2 (en) | 2013-10-22 | 2019-09-19 | Translate Bio, Inc. | mRNA therapy for Argininosuccinate Synthetase Deficiency |
| CN105658242A (en) | 2013-10-22 | 2016-06-08 | 夏尔人类遗传性治疗公司 | MRNA therapy for phenylketonuria |
| WO2015073587A2 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| MX2016009771A (en) | 2014-01-31 | 2016-11-14 | Factor Bioscience Inc | Methods and products for nucleic acid production and delivery. |
| MA39819A (en) | 2014-04-01 | 2017-02-08 | Rubius Therapeutics Inc | Methods and compositions for immunomodulation |
| CN110511927A (en) | 2014-04-25 | 2019-11-29 | 川斯勒佰尔公司 | The purification process of mRNA |
| PT3142643T (en) | 2014-05-15 | 2019-10-28 | Insmed Inc | Methods for treating pulmonary non-tuberculous mycobacterial infections |
| JP6557722B2 (en) | 2014-05-30 | 2019-08-07 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | Biodegradable lipids for delivery of nucleic acids |
| CN111588695A (en) | 2014-06-24 | 2020-08-28 | 川斯勒佰尔公司 | Stereochemically enriched compositions for delivery of nucleic acids |
| US9840479B2 (en) | 2014-07-02 | 2017-12-12 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
| CN104546722B (en) * | 2015-02-10 | 2017-05-24 | 中国医学科学院医药生物技术研究所 | Miriplatin lipidosome and preparation method thereof |
| WO2016131052A1 (en) | 2015-02-13 | 2016-08-18 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| CA2990172A1 (en) | 2015-06-19 | 2016-12-22 | Massachusetts Institute Of Technology | Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell |
| JP6894423B2 (en) | 2015-07-09 | 2021-06-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | Fusible liposome-coated porous silicon nanoparticles |
| US10517823B1 (en) * | 2016-08-10 | 2019-12-31 | Verily Life Sciences Llc | ROS—responsive liposomes for specific targeting |
| US10583083B1 (en) | 2016-08-10 | 2020-03-10 | Verily Life Sciences Llc | ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages |
| WO2018035377A1 (en) | 2016-08-17 | 2018-02-22 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| US11339209B2 (en) | 2016-11-14 | 2022-05-24 | Novartis Ag | Compositions, methods, and therapeutic uses related to fusogenic protein minion |
| MA47603A (en) | 2017-02-27 | 2020-01-01 | Translate Bio Inc | NEW ARNM CFTR WITH OPTIMIZED CODONS |
| EP3595636A4 (en) | 2017-03-16 | 2021-01-13 | Children's Medical Center Corporation | Engineered liposomes as cancer-targeted therapeutics |
| BR112019022016A2 (en) * | 2017-04-19 | 2020-05-12 | Apa- Advanced Technologies Ltd. | FUSOGENIC LIPOSOMES, COMPOSITIONS, KITS AND USE OF THE SAME IN CANCER TREATMENT |
| IL270631B2 (en) | 2017-05-16 | 2024-03-01 | Translate Bio Inc | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
| EP3700965A1 (en) | 2017-10-27 | 2020-09-02 | Massachusetts Institute of Technology | Poly (beta-amino esters) and uses thereof |
| EP3773505A4 (en) | 2018-03-30 | 2021-12-22 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
| CN112930396A (en) | 2018-08-24 | 2021-06-08 | 川斯勒佰尔公司 | Method for purifying messenger RNA |
| CA3117914A1 (en) * | 2018-10-24 | 2020-04-30 | Apa- Advanced Technologies Ltd. | Fusogenic liposomes for selective imaging of tumor cells |
| EP3870629A1 (en) | 2018-10-26 | 2021-09-01 | Massachusetts Institute of Technology | Polymer-lipids and compositions |
| WO2023210671A1 (en) * | 2022-04-26 | 2023-11-02 | 京セラ株式会社 | Copolymer, polymer film, measuring device, and support for measurement |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5136095A (en) * | 1987-05-19 | 1992-08-04 | Syntex (U.S.A.) Inc. | Reversible agglutination mediators |
| JPH0720857B2 (en) * | 1988-08-11 | 1995-03-08 | テルモ株式会社 | Liposome and its manufacturing method |
| US5620689A (en) * | 1989-10-20 | 1997-04-15 | Sequus Pharmaceuuticals, Inc. | Liposomes for treatment of B-cell and T-cell disorders |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| JP3220180B2 (en) * | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | Drug-containing protein-bound liposomes |
| JPH07173079A (en) * | 1992-12-22 | 1995-07-11 | Nippon Oil & Fats Co Ltd | Amphiphatic polyethylene glycol derivative and its use |
| US5395619A (en) * | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
-
1997
- 1997-10-09 TW TW086114833A patent/TW520297B/en not_active IP Right Cessation
- 1997-10-10 AT AT97912775T patent/ATE232086T1/en not_active IP Right Cessation
- 1997-10-10 CA CA002267904A patent/CA2267904C/en not_active Expired - Fee Related
- 1997-10-10 DK DK97912775T patent/DK0932391T3/en active
- 1997-10-10 US US08/949,046 patent/US5891468A/en not_active Expired - Lifetime
- 1997-10-10 AU AU49878/97A patent/AU715063B2/en not_active Ceased
- 1997-10-10 ES ES97912775T patent/ES2191833T3/en not_active Expired - Lifetime
- 1997-10-10 JP JP51862998A patent/JP2001504093A/en not_active Ceased
- 1997-10-10 EP EP97912775A patent/EP0932391B1/en not_active Expired - Lifetime
- 1997-10-10 PT PT97912775T patent/PT932391E/en unknown
- 1997-10-10 DE DE69718924T patent/DE69718924T2/en not_active Expired - Fee Related
- 1997-10-10 IL IL12929297A patent/IL129292A0/en not_active IP Right Cessation
- 1997-10-10 BR BR9712230-0A patent/BR9712230A/en not_active IP Right Cessation
- 1997-10-10 WO PCT/US1997/018838 patent/WO1998016202A2/en active IP Right Grant
-
2002
- 2002-12-19 HK HK02109224.7A patent/HK1047550A1/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9556110B2 (en) | 2008-11-07 | 2017-01-31 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| US9439968B2 (en) | 2012-08-13 | 2016-09-13 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998016202B1 (en) | Fusogenic liposome composition and method | |
| TW520297B (en) | Fusogenic liposome composition and method | |
| US6620805B1 (en) | Delivery of nucleic acids by porphyrins | |
| Pagnan et al. | Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD2-targeted immunoliposomes: antitumor effects | |
| DE69820247T2 (en) | POLYETHYLENE GLYCOL INTERFERON ALPHA CONJUGATES FOR THERAPY OF INFECTIONS | |
| US7195780B2 (en) | Nanoparticle delivery system | |
| CA2157410C (en) | Enhanced circulation effector composition and method | |
| JP2001503396A (en) | Therapeutic liposome compositions and methods | |
| EP0329184A3 (en) | Antimers and antimeric conjugation | |
| Alberts et al. | Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration | |
| EP1140022B8 (en) | Method of administering a compound to multi-drug resistant cells | |
| Gaspar et al. | Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infection | |
| Raffaghello et al. | In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma | |
| Dreaden et al. | RNA‐peptide nanoplexes drug DNA damage pathways in high‐grade serous ovarian tumors | |
| Kole et al. | Neoglycoprotein conjugated liposomes as macrophage specific drug carrier in the therapy of leishmaniasis | |
| CN109091468A (en) | A kind of antibody, polypeptide and Nucleic acid combinations treatment targeting vector and preparation method and purposes | |
| Isonishi et al. | Phase I and pharmacokinetic trial of intraperitoneal etoposide in combination with the multidrug-resistance-modulating agent dipyridamole | |
| EP0552280B1 (en) | Inhibition of viral replication | |
| JPH05506253A (en) | Sustained drug release by topical application of bioadhesive liposomes | |
| WO2023274105A1 (en) | Preparation method for and application of biomimetic nano-protective agent for counteracting cardiotoxicity and systemic toxicity of doxorubicin | |
| CN1032190C (en) | Method for reducing side effects of drug | |
| Newton et al. | Anti-tumor ribonuclease, combined with or conjugated to monoclonal antibody MRK16, overcomes multidrug resistance to vincristine in vitro and in vivo | |
| Obrist et al. | Enhancement of macrophage invasion of tumors by administration of chemotactic factor-antitumor antibody conjugates | |
| KR19990023798A (en) | Antitumor agents | |
| Raymond | Liposomes embark on rescue mission to make highly toxic drugs more useful |